Paxlovid rebound means COVID-19 symptoms return or a test becomes positive again after you initially improved or tested negative. It can happen several days after the five-day treatment course ends. Rebound is often mild, but a renewed positive test or symptoms could mean you can spread the virus, so take precautions and follow your local health guidance.
When Paxlovid rebound can happen
There is no single agreed definition of rebound, and studies have used different ways to identify it. In a 2024 electronic-record study, Daniel Camp, Matthew Caputo, Fabiola Moreno Echevarria and Chad Achenbach looked at 268 adults treated with Paxlovid between January and June 2022. They counted rebound when symptoms clearly improved and then returned or worsened within 30 days. Sixteen people (6%) met that definition; the median time from starting treatment to rebound was 11 days.
That estimate is not a universal rate. Records may miss mild episodes, while studies that check symptoms and viral tests frequently can detect more. For example, a randomized trial at Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, followed adults with mild-to-moderate COVID-19 in Shanghai from December 2022 to January 2023. Among 180 people given Paxlovid, 24.5% had symptom rebound and 21.7% had viral-load rebound under the trial’s definitions. Participants were monitored closely, and people at high risk of severe COVID-19 were excluded. Those figures therefore cannot be applied directly to everyone who takes Paxlovid.
Rebound is not unique to people who take antivirals: COVID-19 can fluctuate without treatment too. A CDC review found rebound had been reported both in treated and untreated people, and its summary of the original Paxlovid trial found no consistent association between treatment and rebound. Current findings do not establish one simple cause or a rate that fits every population and testing approach.
Could you be contagious again?
You may be able to spread COVID-19 during rebound. Symptoms returning or a positive rapid antigen test can indicate renewed viral activity, though neither tells you exactly how infectious you are. If symptoms come back or you test positive after improving, act as though you could pass the virus to others: stay home when possible, avoid close contact, improve ventilation, and wear a well-fitting mask around other people. Be especially careful around anyone at higher risk of severe illness.
Isolation and return-to-work or school rules differ across countries and can change. Check current advice from your national or local public health authority rather than relying on a rule from another region. If you need to be around others, follow that guidance and take extra precautions while symptoms are present or your test is positive.
Why a second course is not routine
A second five-day course may lower viral levels, but that does not automatically mean it improves outcomes that matter to most people. In a randomized, double-blind trial reported by Wuyan Zhang and colleagues, 436 people with mild-to-moderate COVID-19 and a positive rapid test within 14 days of their first course received either another course of Paxlovid or placebo with ritonavir. Retreatment lowered viral RNA more by day five. People retreated also reached two consecutive negative rapid tests a median of one day sooner (four days versus five) and sustained symptom relief one day sooner (eight versus nine days).
However, there were no COVID-related hospitalizations or deaths in either group, and the researchers concluded there was no clear clinical benefit because rebound was usually mild and transient. The results support not routinely taking another course for a typical rebound; they do not settle what is best for every person or every clinical situation. Do not restart or extend Paxlovid on your own.
When to contact a clinician
If you are severely immunocompromised, contact your clinician promptly if symptoms or positive tests return. Your individual risks and treatment options may need assessment; do not assume that findings from studies of mostly general adult populations apply to you. Also seek medical care for severe or worsening symptoms, or if you are concerned about your recovery. A clinician can advise whether further evaluation or treatment is appropriate.
